Phio Pharmaceuticals Announces Dosing of First Patient in
Trial targeting treatment of metastatic melanoma and other solid tumors...
Source: globenewswire.com
📰 Robert Bitterman News
Robert Bitterman News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Robert Bitterman. Real-time updates on events, politics, business and more.
Phio Pharmaceuticals Announces Dosing of First Patient in Collaborative Clinical Trial with AgonOx, Inc. and Providence Cancer Institute
MARLBOROUGH, Mass., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose pr...
Source: businessinsider.com
Phio Pharmaceuticals Announces Dosing of First Patient in Collaborative Clinical Trial with AgonOx, Inc. and Providence Cancer Institute - Phio Pharma (NASDAQ:PHIO)
MARLBOROUGH, Mass., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make
Source: benzinga.com
CURO Group And 2 Other Stocks Under $3 Insiders Are Aggressively Buying - CURO Group Holdings (NYSE:CURO), HOOKIPA Pharma (NASDAQ:HOOK)
The Dow Jones closed lower by over 100 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Source: benzinga.com
Phio Pharmaceuticals Announces Initiation of Collaborative Clinical Trial with PH-762, AgonOx's Tumor Infiltrating Lymphocyte Program (AGX148) and Providence Cancer Institute
/PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is...
Source: prnewswire.com
Phio Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update
/PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is...
United States Ashleyr Robinson Robert Bitterman American Association For Cancer Research Development Expenses American Society Of Gene
Source: prnewswire.com
Marlborough biopharma selects board chair as new CEO
Phio Pharmaceuticals Inc. in Marlborough removed the interim tag from Robert Bitterman’s title on Monday, naming him its new president and CEO after he served in the role on a fill-in basis since September.
Source: wbjournal.com
Phio Pharmaceuticals Appoints Robert Bitterman as President and Chief Executive Officer
/PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is...
Source: prnewswire.com
Phio Pharmaceuticals Announces Positive DMC Recommendation and Continued Enrollment of Advanced Melanoma Study Without Modification
/PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is...
Ashleyr Robinson Robert Bitterman Gustave Roussy Institute Villejuif Company Phase Phio Pharmaceuticals Prnewswire Phio Pharmaceuticals Corp
Source: prnewswire.com
Holy Cross grad aims to lead Phio Pharmaceuticals cancer research into clinical development
Marlborough biopharma Phio Pharmaceuticals is ushering in a new strategic plan seeking to reposition the company from pure discovery research to full development, utilizing clinical trials.
United States Robert Bitterman Gerrit Dispersyn Phio Pharmaceuticals College Of The Holy Cross Cutanea Life Sciences
Source: wbjournal.com